Lundbeck partner soon to seek approval for new Abilify Maintena version
![Photo: Thomas Borberg](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13211320.ece/ALTERNATES/schema-16_9/doc7h5faucdc031chqk5avz.jpg)
The term of Abilify Maintena's patent protection could be substantially extended. Japanese Otsuka, Lundbeck's partner for the drug, is in the process of preparing to seek approval for a new and longer-acting version of the medication.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Covid-stricken US still causing Lundbeck problems
For subscribers